Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate showed no clear difference in adverse events: severe compared with oral chloroquine (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
Oral methotrexate may leads to higher adverse events: minor compared with oral chloroquine (low certainty).
1 finding from 1 review
Serious adverse events ‐ mild disease to quiescent (up to 52 weeks) · IBD patients
It is very uncertain whether oral ferric maltol changes serious adverse events ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether oral ferric maltol changes number of responders ‐ mild disease to quiescent (up to 52 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Hearing ‐ return to normal *Ventilation tubes versus laser myringotomy (6 to 12 months ‐ medium‐term) Adjusted for non‐independence of within‐individual measurements Assumed ICC of 0.5 № of participants: 132 (2 RCTs) · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in hearing ‐ return to normal hearing compared with placebo (moderate certainty).
1 finding from 1 review
RR 1.14 [0.97, 1.33]
Studies not reported
Moderate
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids may leads to lower presence/persistence of OME compared with placebo (low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
It is very uncertain whether oral steroids changes adverse event: systemic corticosteroid side effects compared with placebo (very low certainty).
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Hearing · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Disease‐specific quality of life · children aged 6 months to 12 years with otitis media with effusion (OME)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Presence/persistence of OME · children aged 6 months to 12 years with otitis media with effusion (OME)
Oral steroids showed no clear difference in presence/persistence of OME (3 to 9 months ‐ medium‐term) № of… compared with no treatment (low certainty).
1 finding from 1 review
RR 1.02 [0.89, 1.17]
Studies not reported
Low
Adverse event: systemic corticosteroid side effects · children aged 6 months to 12 years with otitis media with effusion (OME)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Recurrent seizure at 6 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 12 months · children with febrile seizures
Intermittent oral diazepam showed no clear difference in recurrent seizure at 12 months compared with intermittent oral clobazam (low certainty).
1 finding from 1 review
Recurrent seizure at 18 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 24 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 36 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrent seizure at 48 months · children with febrile seizures
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found